Trial Profile
A Randomized Phase II Study Evaluating Efficacy and Safety of 2nd or 3rd Line Treatment by Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant-mesothelioma
- Focus Therapeutic Use
- Acronyms MAPS2
- 25 Feb 2019 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 16 Jan 2019 Status changed from active, no longer recruiting to completed, according to the results published in the Lancet Oncology
- 16 Jan 2019 Primary endpoint (Disease Control rate assessed by CT scan) has been met, according to the results published in the Lancet Oncology